Nebulized fentanyl for palliation of dyspnea in a cystic fibrosis patient

Respiration

Volumn 71, Issue 6, 2004, Pages 646-649

  Graff, Gavin R ^a   Stark, James M ^b   Grueber, Ryan ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Cystic fibrosis; Dyspnea; Fentanyl

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTAZIDIME; CHLORAMPHENICOL; FENTANYL; HELIOX; LEVOFLOXACIN; MEROPENEM; TOBRAMYCIN;

ADOLESCENT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE EXACERBATION; DYSPNEA; FEMALE; HUMAN; NEBULIZATION; OXYGENATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

ADMINISTRATION, INHALATION; ADOLESCENT; ANALGESICS, OPIOID; CYSTIC FIBROSIS; DYSPNEA; FATAL OUTCOME; FEMALE; FENTANYL; HUMANS; PALLIATIVE CARE;

EID: 11844280942     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081769     Document Type: Article

References (15)

1. Manning HL: Dyspnea treatment. Respir Care 2000;45:1342-1351.
2. Janahi IA, Maciejewski SR, Teran JM, Oermann CM: Inhaled morphine to relieve dyspnea in advanced cystic fibrosis lung disease. Pediatr Pulmonol 2000;30:257-259.
3. Cohen SP, Dawson TC: Nebulized morphine as a treatment for dyspnea in a child with cystic fibrosis. Pediatrics 2002;110:e38-e40.
4. Borg GA: Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-381.
5. Dyspnea: Mechanisms, assessment, and management: A consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999;159:321-340.
6. Robinson WM, Ravilly S, Berde C, Wohl ME: End-of-life care in cystic fibrosis. Pediatrics 1997;100/2/1:205-209.
7. Zebraski SE, Kochenash SM, Raffa RB: Lung opioid receptors: Pharmacology and possible target for nebulized morphine in dyspnea. Life Sci 2000;66:2221-2231.
8. Sato H, Sugiyama Y, Sawada Y, Iga T, Hanano M: In vivo evidence for the specific binding of human beta-endorphin to the lung and liver of the rat. Biochem Pharmacol 1988;37:2273-2278.
9. Cabot PJ: Immune-derived opioids and peripheral antinociception. Clin Exp Pharmacol Physiol 2001;28:230-232.
10. Jennings AL, Davies AN, Higgins JP, Broadley K: Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev 2001;4:CD002066.
11. Mestiri M, Lurie A, Frossard N, Lockhart A, Marsac J, Strauch G, Dessanges JF: Effect of inhaled morphine on the bronchial response to isocapnic hyperventilation in patients with allergic asthma. Eur J Clin Pharmacol 1991;41:621.
12. Coyne PJ, Viswanathan R, Smith TJ: Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage 2002;23:157-160.
13. Chrubasik J, Wust H, Friedrich G, Geller E: Absorption and bioavailability of nebulized morphine. Br J Anaesth 1988;61:228-230.
14. Lang E, Jedeikin R: Acute respiratory depression as a complication of nebulised morphine. Can J Anaesth 1998;45:60-62.
15. Kacmarek RM: Care-giver protection from exposure to aerosolized pharmacologic agents. Is it necessary? Chest 1991;100:1104-1105.